In patients with chronic kidney disease, which first-line antihypertensive class is often favored for renal protection?

• A. Thiazide diuretics
• B. Beta blockers
• C. ACE inhibitors or ARBs
• D. Calcium channel blockers

Answer: (C)

In chronic kidney disease, the priority of antihypertensive therapy often is to protect renal function by reducing intraglomerular pressure and proteinuria. Blocking the renin-angiotensin-aldosterone system achieves this most effectively: ACE inhibitors and ARBs dilate the efferent arteriole, lowering filtration pressure, decreasing protein leakage into the urine, and slowing the progression of kidney damage. This renoprotective effect tends to persist beyond simple BP reduction, making these agents the preferred first-line choice when kidney protection is a central goal, especially in patients with proteinuric CKD or diabetic nephropathy.

Other antihypertensive classes can lower blood pressure, but they don’t offer the same targeted renal protection. Thiazide diuretics are great for volume management and BP control, while beta blockers and calcium channel blockers serve specific comorbidity needs, but they don’t provide the same reduction in proteinuria or long-term preservation of renal function as RAAS blockade. In practice, ACE inhibitors or ARBs are used first for their kidney-focused benefits, with other agents added as needed for BP control or comorbid conditions.

Practical notes include monitoring kidney function and potassium after starting or increasing an ACE inhibitor or ARB, and avoiding these agents in certain situations like bilateral renal artery stenosis due to the risk of acute kidney injury.